A detailed history of Ever Source Wealth Advisors, LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Ever Source Wealth Advisors, LLC holds 6,589 shares of BMY stock, worth $380,580. This represents 0.02% of its overall portfolio holdings.

Number of Shares
6,589
Previous 5,695 15.7%
Holding current value
$380,580
Previous $236,000 44.07%
% of portfolio
0.02%
Previous 0.02%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$39.66 - $51.75 $35,456 - $46,264
894 Added 15.7%
6,589 $340,000
Q2 2024

Aug 13, 2024

BUY
$40.25 - $52.99 $28,295 - $37,251
703 Added 14.08%
5,695 $236,000
Q1 2024

Jun 11, 2024

BUY
$47.98 - $54.4 $116,639 - $132,246
2,431 Added 94.92%
4,992 $270,000
Q4 2023

Feb 09, 2024

SELL
$48.48 - $57.85 $99,577 - $118,823
-2,054 Reduced 44.51%
2,561 $131,000
Q3 2023

Nov 03, 2023

BUY
$57.89 - $64.73 $51,001 - $57,027
881 Added 23.59%
4,615 $267,000
Q2 2023

Aug 04, 2023

SELL
$63.71 - $70.74 $59,887 - $66,495
-940 Reduced 20.11%
3,734 $238,000
Q1 2023

May 11, 2023

SELL
$65.71 - $74.53 $71,032 - $80,566
-1,081 Reduced 18.78%
4,674 $323,000
Q4 2022

Feb 09, 2023

BUY
$68.48 - $81.09 $111,074 - $131,527
1,622 Added 39.25%
5,755 $414,000
Q3 2022

Nov 07, 2022

SELL
$0.13 - $76.84 $82 - $48,716
-634 Reduced 13.3%
4,133 $295,000
Q2 2022

Aug 01, 2022

BUY
$72.62 - $79.98 $278,425 - $306,643
3,834 Added 410.93%
4,767 $367,000
Q1 2022

May 25, 2022

BUY
$61.48 - $73.72 $12,910 - $15,481
210 Added 29.05%
933 $68,000
Q4 2021

Feb 07, 2022

BUY
$53.63 - $62.52 $38,774 - $45,201
723 New
723 $45,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Ever Source Wealth Advisors, LLC Portfolio

Follow Ever Source Wealth Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ever Source Wealth Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ever Source Wealth Advisors, LLC with notifications on news.